Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Share News (APH)

  • This share is currently suspended. It was suspended at a price of 64.70
  • There is currently no data for APH

Small Cap round-up: Vislink, Source BioScience, Alliance Pharma..........

Wed, 24th Mar 2010 18:43
New chief executive Duncan Lewis has restructured Vislink's operations so they are based on customer sectors rather than technologies. The core news and entertainment division reported much lower revenues as its major US contract came to an end. The law enforcement division is benefiting from increased spending on surveillance equipment and the marine division is gaining work onshore. Revenues fell from £101m to £94.7m in 2009. The underlying operating profit declined by two-fifths to £5.22m and pre-tax profit slumped from £8.77m to £4.75m. The dividend is unchanged at 1.25p a share. Net cash was £611,000 at the end of 2009. Capitalised development spending increased from £2.95m to £3.2m. The order book was worth £20.3m at the end of 2009. Cost savings will help profits to recover this year. Evolution forecasts that profits will improve to £8.6m in 2010. Asia and the Middle East provide the most opportunities. Vislink is ready to make acquisitions and they are likely to be in Asia so that the company has a base in the region. Healthcare and life sciences services provider Source BioScience moved into profit in 2009. There was a swing from a loss of £300,000 to a profit of £200,000 on revenues that were 11% higher at £12.7m. All three divisions made a positive contribution in the year. Source is investing in DNA sequencing equipment and expects this to be a growth area. The outsourced pharma services operation made its first profit. Alliance Pharma reported a 44% increase in revenues to £31.2m in 2009 thanks to a combination of organic and acquisitive growth. Pre-exceptional profits jumped from £2.4m to £8.6m, although that doesn't include a £2.8m write-off mainly relating to the capitalised development costs of a drug. Alliance specialises in mature drugs and treatments which have a solid revenue base. Some of its drugs are more than 50 years old but they still have significant revenues. The recent purchase of Cambridge Laboratories for up to £16.4m has added cancer drugs to the portfolio. A much-improved second half performance helped eg solutions to return to profit in the year to January 2010. The operations management software supplier reported a 13% increase in revenues to £4.15m. A loss of £753,000 was turned into a profit of £99,000 in 2009. Higher gross margins and cost cutting were behind the improvement. More software licences were sold in the most recent period. Weak construction demand has hit trading at quantity surveyor Baqus and although work is being won it is at lower margins than in the past. The order book is flat at £8m. Management had already warned that the interim figures would be disappointing. Revenues fell from £3.98m to £3.85m in the six months to December 2009. A profit of £365,000 has turned into a loss of £470,000, including an exceptional charge for redundancies and office closures.

Related News

Alliance Pharma loss narrows in 2024 due to reduced impairment charges
8 Apr 2025

Alliance Pharma loss narrows in 2024 due to reduced impairment charges

(Alliance News) - Alliance Pharma PLC on Tuesday reported a narrowed loss for 2024 despite a decline in revenue, due to a reduction in impairment char...

Alliance Pharma confident despite softer sales
8 Apr 2025

Alliance Pharma confident despite softer sales

(Sharecast News) - Alliance Pharma posted weaker full-year revenues on Tuesday, but insisted it remained well-positioned for medium-term growth.

Alliance Pharma board backs final GBP362 million takeover bid
10 Mar 2025

Alliance Pharma board backs final GBP362 million takeover bid

(Alliance News) - Alliance Pharma PLC on Monday said it has agreed to a final increased cash offer of 64.75 pence per share from Dbay Advisors Ltd and...

Alliance Pharma News

UK Earnings, Trading Statements Calendar - Next 7 Days
10 Jul 2019

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 11 July Kenmare ResourcesHalf Year ProductionMcBrideTrading GroupFull

Alliance Pharma Founder & Former Chief Executive John Dawson Departs
1 Jul 2019

Alliance Pharma Founder & Former Chief Executive John Dawson Departs

(Alliance News) - Alliance Pharma PLC said on Monday founder & former chief executive John Dawson decided to step down from the board.Dawson, who was ...

UK Shareholder Meetings Calendar - Next 7 Days
16 May 2019

UK Shareholder Meetings Calendar - Next 7 Days

Friday 17 MayRestaurant GroupBank of Georgia GroupCentaur MediaCairn Continental 20

Alliance Pharma's 'Xonvea' gets approval in Ireland
10 Apr 2019

Alliance Pharma's 'Xonvea' gets approval in Ireland

(Sharecast News) - Alliance Pharma announced on Wednesday that 'Xonvea' has gained marketing approval in the Republic of Ireland from the country's me...

Alliance Pharma Gets Approval For Anti-Nausea Drug Xonvea In Ireland
10 Apr 2019

Alliance Pharma Gets Approval For Anti-Nausea Drug Xonvea In Ireland

LONDON (Alliance News) - Alliance Pharma PLC on Wednesday said its Xonvea drug has been approved in Ireland to treat nausea and vomiting of pregnancy....

Alliance Pharma Raises Annual Dividend Amid Strong Revenue Growth
26 Mar 2019

Alliance Pharma Raises Annual Dividend Amid Strong Revenue Growth

LONDON (Alliance News) - Alliance Pharma on Tuesday raised its dividend for 2018 amid a strong revenue performance, though profit fell due to impairme...

UK Earnings, Trading Statements Calendar - Next 7 Days
19 Mar 2019

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 20 March KingfisherFull Year ResultsCentaur MediaFull Year GroupHalf

Alliance Pharma's revenues climb as 'star' products shine
21 Jan 2019

Alliance Pharma's revenues climb as 'star' products shine

(Sharecast News) - Alliance Pharma on Monday reported a jump in revenue after a strong performance from its 'star' products and newly acquired Nizoral...